

ABSTRACT

USE OF SECRETIN-RECEPTOR LIGANDS IN TREATMENT OF CYSTIC
FIBROSIS (CF) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

5

The invention is based on the finding that the secretin
receptor is expressed in tissues present in the distal lung of
humans. In patient with CF, levels of the receptor are
elevated compared to normal tissue. Treatment of tissue by
10 secretin stimulates the movement of negative ions in the
tissue. The invention provides methods of treatment of cystic
fibrosis or COPD in a patient by administering to said patient
an effective amount of an agent which triggers anion efflux in
respiratory tissue via the activation of a secretin receptor.